登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C29H26ClFN4O4S
化学文摘社编号:
分子量:
581.06
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
NACRES:
NA.21
Form:
solid
description
AldrichCPR
form
solid
SMILES string
CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O
InChI
1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChI key
BCFGMOOMADDAQU-UHFFFAOYSA-N
Gene Information
human ... EGFR(1956), ERBB2(2064)
General description
拉帕替尼是一种以表皮生长因子受体ErbB1和ErbB-2为靶点的酪氨酸激酶抑制剂。据报道它与曲妥珠单抗联合使用时在乳腺癌中具有互补作用和抗肿瘤增效活性。
Other Notes
请注意,Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现的研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方承担确认产品标识和纯度的责任。所有销售均为最终销售。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款,但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中,SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保,包括:(A)适销性担保;(B)特定用途适用性担保;或(C)未侵犯第三方知识产权担保。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款,但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中,SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保,包括:(A)适销性担保;(B)特定用途适用性担保;或(C)未侵犯第三方知识产权担保。
Still not finding the right product?
Explore all of our products under 拉帕替尼
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 4 - Eye Irrit. 2 - Lact.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, et al.
The Lancet, 379(9816), 633-640 (2012)
Melinda Halasz et al.
Science signaling, 9(455), ra114-ra114 (2016-11-24)
Signal transduction networks are often rewired in cancer cells. Identifying these alterations will enable more effective cancer treatment. We developed a computational framework that can identify, reconstruct, and mechanistically model these rewired networks from noisy and incomplete perturbation response data
Sydney M Shaffer et al.
Nature, 546(7658), 431-435 (2017-06-14)
Therapies that target signalling molecules that are mutated in cancers can often have substantial short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can result from secondary mutations, but in other cases
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| CDS022971-25MG | 04061828994106 |
